RU2015120217A - Замещенные 1,6-нафтиридины - Google Patents
Замещенные 1,6-нафтиридины Download PDFInfo
- Publication number
- RU2015120217A RU2015120217A RU2015120217A RU2015120217A RU2015120217A RU 2015120217 A RU2015120217 A RU 2015120217A RU 2015120217 A RU2015120217 A RU 2015120217A RU 2015120217 A RU2015120217 A RU 2015120217A RU 2015120217 A RU2015120217 A RU 2015120217A
- Authority
- RU
- Russia
- Prior art keywords
- naphthyridine
- carboxamide
- chlorophenyl
- phenyl
- methylsulfonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12193311.3 | 2012-11-20 | ||
| EP12193311 | 2012-11-20 | ||
| PCT/EP2013/074012 WO2014079787A1 (en) | 2012-11-20 | 2013-11-18 | Substituted 1,6-naphthyridines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015120217A true RU2015120217A (ru) | 2017-01-10 |
Family
ID=47189816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015120217A RU2015120217A (ru) | 2012-11-20 | 2013-11-18 | Замещенные 1,6-нафтиридины |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9657014B2 (enExample) |
| EP (1) | EP2922540A1 (enExample) |
| JP (1) | JP2016505534A (enExample) |
| KR (1) | KR20150085538A (enExample) |
| CN (1) | CN104812387A (enExample) |
| AR (1) | AR093519A1 (enExample) |
| BR (1) | BR112015011094A2 (enExample) |
| CA (1) | CA2890685A1 (enExample) |
| HK (1) | HK1207317A1 (enExample) |
| MX (1) | MX2015006364A (enExample) |
| RU (1) | RU2015120217A (enExample) |
| TW (1) | TW201425312A (enExample) |
| WO (1) | WO2014079787A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2838857C2 (ru) * | 2019-01-03 | 2025-04-22 | Юниверсити Оф Питтсбург - Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн | Способы и материалы для повышения уровней полипептида фактора транскрипции eb |
| US12286442B2 (en) | 2019-01-03 | 2025-04-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods and materials for increasing transcription factor eb polypeptide levels |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI529171B (zh) * | 2013-07-29 | 2016-04-11 | 赫孚孟拉羅股份公司 | １，７－萘啶衍生物 |
| JP2017522324A (ja) * | 2014-07-17 | 2017-08-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 新規ナフチリジン及びイソキノリンならびにｃｄｋ８／１９阻害剤としてのその使用 |
| CA2974874A1 (en) * | 2015-02-11 | 2016-08-18 | Basilea Pharmaceutica International AG | Substituted mono- and polyazanaphthalene derivatives and their use |
| CN108299425B (zh) * | 2015-03-24 | 2020-09-18 | 上海璎黎药业有限公司 | 稠环衍生物、其制备方法、中间体、药物组合物及应用 |
| JP6917989B2 (ja) * | 2015-11-06 | 2021-08-11 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 神経学的疾患を処置するためのムスカリン受容体４（ｍ４）アンタゴニストとしての、ｎ−［２−（１−ベンジルピペリジン−４−イル）エチル］−４−（ピラジン−２−イル）−ピペラジン−１−カルボキサミド誘導体および関連化合物 |
| EA039638B1 (ru) * | 2016-01-06 | 2022-02-21 | Нейрокрин Байосайенсиз, Инк. | Антагонисты мускаринового рецептора 4 и способы их применения |
| EP3591040A4 (en) | 2017-03-03 | 2020-11-11 | Kyoto University | METHOD OF PRODUCTION OF PANCREATIC PROGENITOR CELLS |
| US12486250B2 (en) | 2019-12-06 | 2025-12-02 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
| US20240262831A1 (en) * | 2020-12-18 | 2024-08-08 | Vova Ida Therapeutics, Inc. | Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders |
| WO2025252732A1 (en) * | 2024-06-04 | 2025-12-11 | Syngenta Crop Protection Ag | Nitrogen-containing 6-membered bicyclic derivatives with microbiocidal activity |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9605437D0 (en) | 1996-03-15 | 1996-05-15 | Iaf Biochem Int | Cytomegalovirus inhibiting compounds |
| EP1037633B1 (en) * | 1997-12-11 | 2003-09-10 | Biochem Pharma Inc. | Antiviral compounds |
| AU2002218902A1 (en) | 2000-12-27 | 2002-07-08 | Shire Biochem Inc. | Macrocyclic anti-viral compounds |
| CA2575571A1 (en) * | 2004-08-03 | 2006-02-16 | Serenex, Inc. | 2,8-disubstituted naphthyridine derivatives |
| FR2904317A1 (fr) | 2006-07-27 | 2008-02-01 | Inst Nat Sante Rech Med | Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques |
| US20080242694A1 (en) | 2006-09-18 | 2008-10-02 | D Sidocky Neil R | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith |
| WO2008046072A2 (en) | 2006-10-13 | 2008-04-17 | The Board Of Regents Of The University Of Texas System | Chemical inducers of neurogenesis |
| US9095572B2 (en) | 2009-01-09 | 2015-08-04 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| CN102325754B (zh) * | 2009-01-19 | 2014-03-12 | 第一三共株式会社 | 含杂原子的环状化合物 |
| CA2754058A1 (en) * | 2009-03-02 | 2010-09-10 | Sirtris Pharmaceuticals, Inc. | 8-substituted quinolines and related analogs as sirtuin modulators |
| BRPI1013988A2 (pt) | 2009-04-06 | 2016-04-05 | Daiichi Sankyo Co Ltd | composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo |
| JP2012036168A (ja) | 2010-07-15 | 2012-02-23 | Daiichi Sankyo Co Ltd | ヘテロ原子を有する環状化合物を含有する医薬組成物 |
-
2013
- 2013-11-18 RU RU2015120217A patent/RU2015120217A/ru not_active Application Discontinuation
- 2013-11-18 CN CN201380060294.0A patent/CN104812387A/zh active Pending
- 2013-11-18 EP EP13795705.6A patent/EP2922540A1/en not_active Withdrawn
- 2013-11-18 MX MX2015006364A patent/MX2015006364A/es unknown
- 2013-11-18 KR KR1020157016208A patent/KR20150085538A/ko not_active Ceased
- 2013-11-18 BR BR112015011094A patent/BR112015011094A2/pt not_active IP Right Cessation
- 2013-11-18 AR ARP130104234A patent/AR093519A1/es unknown
- 2013-11-18 HK HK15108069.2A patent/HK1207317A1/xx unknown
- 2013-11-18 TW TW102141946A patent/TW201425312A/zh unknown
- 2013-11-18 JP JP2015543399A patent/JP2016505534A/ja active Pending
- 2013-11-18 WO PCT/EP2013/074012 patent/WO2014079787A1/en not_active Ceased
- 2013-11-18 CA CA2890685A patent/CA2890685A1/en not_active Abandoned
-
2015
- 2015-05-20 US US14/717,109 patent/US9657014B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2838857C2 (ru) * | 2019-01-03 | 2025-04-22 | Юниверсити Оф Питтсбург - Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн | Способы и материалы для повышения уровней полипептида фактора транскрипции eb |
| US12286442B2 (en) | 2019-01-03 | 2025-04-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods and materials for increasing transcription factor eb polypeptide levels |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150085538A (ko) | 2015-07-23 |
| HK1207317A1 (en) | 2016-01-29 |
| BR112015011094A2 (pt) | 2017-07-11 |
| JP2016505534A (ja) | 2016-02-25 |
| MX2015006364A (es) | 2015-10-05 |
| TW201425312A (zh) | 2014-07-01 |
| AR093519A1 (es) | 2015-06-10 |
| US20150252044A1 (en) | 2015-09-10 |
| CA2890685A1 (en) | 2014-05-30 |
| EP2922540A1 (en) | 2015-09-30 |
| CN104812387A (zh) | 2015-07-29 |
| US9657014B2 (en) | 2017-05-23 |
| WO2014079787A1 (en) | 2014-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2365588C2 (ru) | Хиназолиновые соединения | |
| JP2013539777A5 (enExample) | ||
| RU2015150946A (ru) | Новые соединения для селективных ингибиторов гистондеацетилазы и фармацевтическая композиция, включающая такие соединения | |
| JP2016517878A5 (enExample) | ||
| JP2019523233A5 (enExample) | ||
| US20210128723A1 (en) | Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors | |
| RU2014151009A (ru) | Пиразолопиримидоновые и пиразолопиридоновые ингибиторы танкиразы | |
| JP2017502940A5 (enExample) | ||
| RU2014139601A (ru) | Ингибиторы серин/треониновых киназ | |
| CA2984259A1 (en) | Combinations of inhibitors of irak4 with inhibitors of btk | |
| JP2019514878A5 (enExample) | ||
| JP2006502112A5 (enExample) | ||
| JP2017525757A5 (enExample) | ||
| US11660301B2 (en) | Combination of ATR kinase inhibitors with PARP inhibitors | |
| RU2012137956A (ru) | Производные пиперидинов | |
| RU2012134306A (ru) | Азотосодержащие производные гетероарилов | |
| JP2012501312A5 (enExample) | ||
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| JP2019505595A5 (enExample) | ||
| RU2019123319A (ru) | Пиразолопиримидины и способы их применения | |
| RU2011114487A (ru) | Гетероциклические соединения как ингибиторы протеинкиназы | |
| RU2013135477A (ru) | Гетероциклические соединения и их применение в качестве ингибиторов киназы-3 гликогенсинтазы | |
| JP2018532788A5 (enExample) | ||
| JP2017501983A5 (enExample) | ||
| RU2016104890A (ru) | Производные 1,7-нафтиридина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180329 |